PacBio and TychoBio Partnered for RNA Therapy Research
The companies have joined forces to use high-fidelity sequencing to train artificial intelligence models for rare diseases.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you believe the integration of AI into drug discovery will significantly improve medical treatment outcomes?
PacBio and TychoBio have launched a collaboration to generate extensive full-length RNA sequencing data. This partnership aims to leverage artificial intelligence for the development of safer and more efficient rare disease therapies.
Why it matters
By integrating high-fidelity sequencing data into AI training, the project seeks to improve the prediction of therapeutic compound efficacy. This approach aims to reduce potential unintended effects in next-generation RNA drug candidates.
The collaboration utilizes PacBio HiFi and Kinnex sequencing technologies to process more than 10,000 samples. The data will map transcriptome changes across multiple cell types to inform future RNA-targeting compound designs.
The players
PacBio
Headquartered in Menlo Park, California, the company specializes in high-fidelity long-read sequencing technologies.
TychoBio
Operating out of Paris, France, this biotechnology firm focuses on designing RNA-based therapeutics through advanced computational modeling.
The details
TychoBio will utilize the sequencing platform to test candidate therapies and monitor resulting changes in the transcriptome. The companies intend to expand this research beyond rare diseases to include siRNA and other RNA-targeting therapeutic classes.
Timeline
October 6, 2026: PacBio and TychoBio announced their collaboration.
The Tech Race
This partnership underscores the industry-wide transition toward using deep genomic data to train predictive artificial intelligence models in drug discovery. It positions these firms at the forefront of a technological race to replace trial-and-error laboratory testing with computational design.
This development could eventually lead to faster access to effective, safer treatment options for patients suffering from rare genetic conditions. By digitizing the drug design process, the collaboration targets significant improvements in both the accuracy and speed of pharmaceutical research.
The takeaway
The union of advanced sequencing and artificial intelligence represents a major shift toward high-throughput digital medicine. Researchers and patients can expect this data-heavy approach to become a standard framework for overcoming the historical challenges of therapeutic safety and efficacy.
Further reading
Learn more about the latest industry developments in the Biotech section.
Live Poll
Do you believe the integration of AI into drug discovery will significantly improve medical treatment outcomes?
